- Home
- LOMA vs ADPT Comparison
LOMA vs ADPT Comparison
Compare LOMA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOMA
- ADPT
- Stock Information
- Founded
- LOMA 1926
- ADPT 2009
- Country
- LOMA Argentina
- ADPT United States
- Employees
- LOMA N/A
- ADPT N/A
- Industry
- LOMA Building Materials
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOMA Industrials
- ADPT Health Care
- Exchange
- LOMA Nasdaq
- ADPT Nasdaq
- Market Cap
- LOMA 1.5B
- ADPT 1.2B
- IPO Year
- LOMA 2017
- ADPT 2019
- Fundamental
- Price
- LOMA $10.72
- ADPT $7.62
- Analyst Decision
- LOMA Sell
- ADPT Buy
- Analyst Count
- LOMA 2
- ADPT 5
- Target Price
- LOMA $6.55
- ADPT $9.10
- AVG Volume (30 Days)
- LOMA 399.0K
- ADPT 1.9M
- Earning Date
- LOMA 03-06-2025
- ADPT 05-06-2025
- Dividend Yield
- LOMA N/A
- ADPT N/A
- EPS Growth
- LOMA 1393.92
- ADPT N/A
- EPS
- LOMA 1.28
- ADPT N/A
- Revenue
- LOMA $678,156,086.00
- ADPT $178,957,000.00
- Revenue This Year
- LOMA N/A
- ADPT $21.21
- Revenue Next Year
- LOMA N/A
- ADPT $21.98
- P/E Ratio
- LOMA $8.25
- ADPT N/A
- Revenue Growth
- LOMA 65.62
- ADPT 5.10
- 52 Week Low
- LOMA $5.70
- ADPT $2.28
- 52 Week High
- LOMA $13.79
- ADPT $8.95
- Technical
- Relative Strength Index (RSI)
- LOMA 44.08
- ADPT 47.75
- Support Level
- LOMA $10.23
- ADPT $6.26
- Resistance Level
- LOMA $10.95
- ADPT $8.49
- Average True Range (ATR)
- LOMA 0.53
- ADPT 0.74
- MACD
- LOMA -0.02
- ADPT -0.14
- Stochastic Oscillator
- LOMA 33.51
- ADPT 50.84
About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue Derives from Cement, masonry cement, and lime segment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).